市場調查報告書
商品編碼
1295345
全球癌症診斷市場-2023年至2028年預測Global Cancer Diagnostics Market - Forecasts from 2023 to 2028 |
癌症診斷市場是指涉及用於診斷癌症的測試和技術的開發、生產和商業化的醫療行業領域。 這包括廣泛的診斷工具,例如成像測試(例如 X 射線、CT 掃描、MRI 掃描)、血液測試、活組織檢查和分子診斷測試(例如基因測試和腫瘤標誌物測試)。 癌症診斷市場是醫療保健行業的一個重要領域,因為早期準確的癌症診斷對於有效治療和改善患者預後至關重要。 癌症診斷市場的主要參與者包括 BioMerieux SA、F. Hoffmann-La Roche Ltd、Sienna Cancer Diagnostics、Insight Medical Genetics 等。 這些公司大力投資研發,開發新技術和解決方案,以滿足不斷增長的需求。
癌症是全世界死亡的主要原因,其發病率正在以驚人的速度增長。 據世界衛生組織(WHO)稱,2020年,將有約1930萬新發癌症病例和1000萬癌症相關死亡病例。 此外,預計未來20年新發癌症病例數將增加47%,到2040年新發病例數將超過2800萬。 隨著癌症患者數量的不斷增加,人們越來越需要更有效和高效的診斷工具來早期檢測和診斷癌症。 癌症的早期發現對於改善患者的預後至關重要,因為它可以進行早期干預和早期治療,並且可以增加獲得良好結果的可能性。
例如,2021 年,美國 FDA 授予 Grail Inc. 用於早期癌症檢測的液體活檢測試突破性器械稱號。 這一稱號旨在促進新技術的開發和審查,這些新技術顯示出為危及生命和不可逆轉的衰弱疾病提供更有效的診斷、治療和預防的潛力。
從診斷程序來看,癌症診斷市場主要包括臨床測試、影像學測試和活檢。 預計臨床測試領域將在預測期內佔據重要的市場份額。 臨床檢測部分進一步分為血液檢測、尿液檢測和基因檢測。
近年來,乳腺癌診斷工具和技術的開發投入快速增加,乳腺癌診斷藥物市場有望進一步增長。 根據國防部乳腺癌研究計劃報告(2021 年 10 月),截至 2020 年,女性乳腺癌是全球最常診斷的癌症,估計有 230 萬新發病例。我在這裡。 到 2021 年,僅在美國就有大約 281,550 名女性和 2,650 名男性被診斷出患有浸潤性乳腺癌。 隨著乳腺癌患者數量的增加,對能夠早期發現和及時治療的癌症診斷技術和產品的需求不斷增長。
根據全球癌症觀測站(GCO)的數據,人口最多的大陸亞洲將在2020年新增癌症病例數最高,約為950萬例。 與此同時,在北美和歐洲,同年新增癌症患者人數超過650萬。 菸酒消費量增加、久坐的生活方式、不健康的飲食習慣以及遺傳因素導緻美國癌症患者數量大幅增加。 例如,根據美國癌症協會提供的數據,美國新診斷癌症病例為190萬例,而2020年報告的新發病例為180萬例,相比之下增加了5.6%。 該消息來源還估計,2021 年癌症死亡人數估計為 6,085,570 人,增加了 2,050 人。 癌症診斷病例和死亡率的增加將推動對癌症早期發現的診斷和篩查活動的需求,從而推動美國癌症診斷市場的增長。
The cancer diagnostics market refers to the healthcare industry segment that deals with the development, production, and commercialization of tests and technologies used to diagnose cancer. This includes a wide range of diagnostic tools, including imaging tests (such as X-rays, CT scans, and MRI scans), blood tests, biopsies, and molecular diagnostic tests (such as genetic and tumor marker tests). The cancer diagnostics market is an important segment of the healthcare industry, as early and accurate cancer diagnosis is crucial for effective treatment and improved patient outcomes. Key players in the cancer diagnostics market include bioMerieux SA, F. Hoffmann-La Roche Ltd, Sienna Cancer Diagnostics, and Insight Medical Genetics. These companies are investing heavily in research and development to develop new technologies and solutions to meet the growing demand.
Cancer is a leading cause of death worldwide, and the incidence of the disease is increasing alarmingly. According to the World Health Organization (WHO), there were approximately 19.3 million new cancer cases and 10 million cancer-related deaths in 2020. Furthermore, it is estimated that the number of new cancer cases will increase by 47% in the next two decades, with over 28 million new cases expected by 2040. As the number of cancer cases continues to rise, there is a growing need for more effective and efficient diagnostic tools to detect and diagnose the disease at an early stage. Early cancer detection is crucial for improving patient outcomes, as it enables earlier intervention and treatment, which can increase the chances of a positive outcome.
For instance, in 2021, the US FDA granted Breakthrough Device designation to Grail Inc.'s liquid biopsy test for early cancer detection. This designation is intended to expedite the development and review of new technologies that demonstrate the potential to provide more effective diagnosis, treatment, or prevention of life-threatening or irreversibly debilitating diseases.
By diagnostic procedures, the global cancer diagnostics market mainly comprises laboratory tests, imaging procedures, and biopsy. During the forecast period, the laboratory test segment is expected to hold a considerable market share. The laboratory test diagnostic procedures segment is further categorized into blood, urine, and genetic tests.
In recent years, there has been a surge in investment in the development of diagnostic tools and technologies for breast cancer, which is expected to fuel further growth in the breast cancer diagnostics market. According to a report by the Department of Defense Breast Cancer Research Program, October 2021, as of 2020, female breast cancer has become the most diagnosed cancer globally, with an estimated 2.3 million new cases. In 2021, about 281,550 women and 2,650 males will be diagnosed with invasive breast cancer in the United States alone. As the number of breast cancer patients grows, there is a heightened demand for cancer diagnostic technologies and products to ensure early detection and prompt treatment.
By geography, the global cancer diagnostics market has been analyzed into North America, South America, Europe, Asia Pacific, and Middle East and Africa.According to data from the Global Cancer Observatory (GCO), Asia, the most populated continent, accounted for the highest number of new cancer cases in 2020, with almost 9.5 million new cases. Meanwhile, North America and Europe combined for more than 6.5 million new cancer cases in the same year. The number of cancer cases has shown significant growth in the US owing to growing alcohol & tobacco consumption, sedentary lifestyle, unhealthy eating habits, and genetic factors. For instance, according to the data provided by the American Cancer of Society, the estimated number of new cancer-diagnosed cases in the US stood at 1.9 million which represented a 5.6% increase in newly diagnosed cases in comparison to 1.8 million new cases reported in 2020. Also, as per the same source, the estimated number of cancer deaths in 2021 stood at 6,08,570, signifying an increase of 2,050 in the number of deaths. Such an increase in cancer-diagnosed cases and the death rate will propel the demand for diagnostics and screening activities for early cancer detection, thereby boosting the market growth of cancer diagnostics in the United States.